Predict the HC50 of any modified peptide.
HemoPI-MOD2 evaluates therapeutic peptide safety by classifying hemolytic activity and predicting continuous pHC50 scores (−log10 HC50), defining the exact concentration causing 50% human red blood cell lysis. Submitting sequences in MAP format screens variants natively or via internal chemistry mapping to identify safe candidates.
HC50 is the concentration causing 50% hemolysis — the inflection of this curve. HemoPI-MOD2 predicts pHC50 (−log HC50) directly, or classifies a peptide relative to it.
Hemolysis in Drug Development
Peptides are highly targeted therapeutic agents, but their clinical utility is frequently limited by hemolysis — the premature destruction of red blood cells. Assessing hemolytic toxicity is an important safety step in evaluating peptide drug candidates. HemoPI-MOD2 accelerates this process by providing fast machine learning screens prior to wet-lab assays.
Glance at HemoPI-MOD2
Quick walkthrough on inputting sequences, adjusting decision thresholds, and reviewing predictions.
Why HemoPI-MOD2
Native MAP Support
Paste chemically modified variants natively. Structural translation is handled completely inside the tool, eliminating manual topology assembly.
Chemistry-Aware Screening
Utilizes internal descriptor mapping, capturing structural details that standard sequence-only algorithms miss.